#BEGIN_DRUGCARD DB04561

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C10H20NO9P

# Chemical_IUPAC_Name:
[(2S,4R,5S,6R)-5-acetamido-4-hydroxy-6-[(1R,2S)-1,2,3-trihydroxypropyl]oxan-2-yl]phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
4-Acetamido-2,4-Didexoy-D-Glycero-Beta-D-Galacto-Octopyranosylphosphonic Acid

# HET_ID:
AXP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C10H20NO9P/c1-4(13)11-8-5(14)2-7(21(17,18)19)20-10(8)9(16)6(15)3-12/h5-10,12,14-16H,2-3H2,1H3,(H,11,13)(H2,17,18,19)/t5-,6+,7+,8+,9-,10-/m1/s1

# InChI_Key:
InChIKey=QITAGYVZDNZULE-JPZACNAASA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4561

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
329.2409

# Molecular_Weight_Mono:
329.087567755

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1DIL

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.4

# Predicted_LogS:
-1

# Predicted_Water_Solubility:
2.98e+01 g/l

# Primary_Accession_No:
DB04561

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46937010

# PubChem_Substance_ID:
46506811

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00595

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)N[C@H]1[C@H](O)C[C@@H](O[C@H]1[C@H](O)[C@@H](O)CO)P(O)(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:27 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M55342

# Drug_Target_1_GenBank_ID_Protein:
531224

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
nanH

# Drug_Target_1_Gene_Sequence:
>1149 bp
ATGACTGTAGAAAAATCCGTGGTTTTTAAAGCTGAAGGTGAGCATTTTACTGATCAAAAA
GGCAATACTATTGTCGGTAGCGGCTCTGGGGGAACAACCAAATATTTTCGAATTCCAGCA
ATGTGTACAACCTCAAAAGGTACCATTGTTGTATTTGCTGATGCGCGCCATAACACTGCC
AGCGATCAGTCCTTTATTGACACAGCGGCGGCCCGTAGCACAGATGGAGGGAAAACCTGG
AATAAAAAAATTGCGATTTATAATGACCGTGTCAACAGTAAACTTTCCCGCGTCATGGAT
CCCACATGCATCGTGGCGAATATTCAGGGAAGAGAAACAATCTTAGTCATGGTTGGCAAA
TGGAATAATAATGATAAAACATGGGGCGCATACAGAGATAAGGCTCCAGACACTGACTGG
GATTTGGTTTTATATAAATCAACCGATGATGGCGTTACCTTTTCAAAGGTGGAAACGAAC
ATCCATGATATAGTAACTAAAAATGGAACGATATCTGCAATGCTTGGCGGTGTTGGATCT
GGTCTTCAGCTAAATGACGGTAAACTGGTTTTCCCGGTACAAATGGTTCGCACTAAAAAT
ATCACCACAGTTCTGAATACATCATTCATATACTCCACTGATGGAATAACATGGTCATTG
CCATCAGGATACTGTGAGGGTTTTGGTTCAGAAAATAACATCATAGAATTTAATGCCTCT
TTGGTTAATAACATCAGAAACTCTGGCCTCCGCCGTTCTTTTGAAACAAAAGATTTTGGA
AAAACATGGACTGAGTTTCCTCCGATGGACAAGAAGGTTGACAACAGGAATCATGGAGTA
CAAGGTTCAACAATTACTATTCCATCAGGCAATAAACTTGTCGCGGCTCACTCATCCGCG
CAGAACAAGAATAATGACTATACCAGAAGTGATATATCTCTCTACGCTCACAATTTATAC
TCCGGGGAAGTAAAGTTAATTGATGCTTTTTATCCGAAAGTCGGTAATGCCAGTGGCGCG
GGTTACTCTTGTCTTTCATATCGTAAAAATGTAGATAAAGAAACACTGTATGTTGTCTAT
GAAGCCAATGGAAGTATTGAGTTCCAGGACCTTAGCCGTCATTTACCAGTAATAAAATCA
TACAATTAA

# Drug_Target_1_General_Function:
Involved in exo-alpha-sialidase activity

# Drug_Target_1_General_References:
11677609	McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK: Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature. 2001 Oct 25;413(6858):852-6.
1518058	Taylor G, Vimr E, Garman E, Laver G: Purification, crystallization and preliminary crystallographic study of neuraminidase from Vibrio cholerae and Salmonella typhimurium LT2. J Mol Biol. 1992 Aug 20;226(4):1287-90.
1602967	Hoyer LL, Hamilton AC, Steenbergen SM, Vimr ER: Cloning, sequencing and distribution of the Salmonella typhimurium LT2 sialidase gene, nanH, provides evidence for interspecies gene transfer. Mol Microbiol. 1992 Apr;6(7):873-84.
8234325	Crennell SJ, Garman EF, Laver WG, Vimr ER, Taylor GL: Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9852-6.
8656428	Crennell SJ, Garman EF, Philippon C, Vasella A, Laver WG, Vimr ER, Taylor GL: The structures of Salmonella typhimurium LT2 neuraminidase and its complexes with three inhibitors at high resolution. J Mol Biol. 1996 Jun 7;259(2):264-80.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2942

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
42073

# Drug_Target_1_Name:
Sialidase

# Drug_Target_1_Number_of_Residues:
382

# Drug_Target_1_PDB_ID:
1DIM

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02012	BNR

# Drug_Target_1_Protein_Sequence:
>Sialidase
MTVEKSVVFKAEGEHFTDQKGNTIVGSGSGGTTKYFRIPAMCTTSKGTIVVFADARHNTA
SDQSFIDTAAARSTDGGKTWNKKIAIYNDRVNSKLSRVMDPTCIVANIQGRETILVMVGK
WNNNDKTWGAYRDKAPDTDWDLVLYKSTDDGVTFSKVETNIHDIVTKNGTISAMLGGVGS
GLQLNDGKLVFPVQMVRTKNITTVLNTSFIYSTDGITWSLPSGYCEGFGSENNIIEFNAS
LVNNIRNSGLRRSFETKDFGKTWTEFPPMDKKVDNRNHGVQGSTITIPSGNKLVAAHSSA
QNKNNDYTRSDISLYAHNLYSGEVKLIDDFYPKVGNASGAGYSCLSYRKNVDKETLYVVY
EANGSIEFQDLSRHLPVIKSYN

# Drug_Target_1_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Cleaves the terminal sialic acid (N-acetyl neuraminic acid) from carbohydrate chains in glycoproteins providing free sialic acid which can be used as carbon and energy sources. Sialidases have been suggested to be pathogenic factors in microbial infections

# Drug_Target_1_SwissProt_ID:
P29768

# Drug_Target_1_SwissProt_Name:
NANH_SALTY

# Drug_Target_1_Synonyms:
EC 3.2.1.18
N-acylneuraminate glycohydrolase
NANase
Neuraminidase
STNA

# Drug_Target_1_Theoretical_pI:
8.53

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB04561
